Clinical · Molecular biology · Bioinfo & AI
STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma
Summary
Cervical adenocarcinoma is linked to poorer survival and reduced response to immunotherapy. This study identified STK11 alterations, including mutations and focal deletions, as a distinct feature of HPV-positive cervical adenocarcinomas, affecting 23% of these tumors. These alterations are associated with a younger age at diagnosis, poorer overall survival, and inferior outcomes following immune checkpoint inhibitor therapy. Comprehensive genomic analyses revealed complex structural rearrangements involving chromosome 19p and STK11. These findings define an aggressive molecular subgroup and have implications for molecular classification and future targeted therapeutic strategies.
Critical appraisal
Clinical. This study identifies STK11 alterations as a negative prognostic and predictive biomarker in cervical adenocarcinoma patients, particularly regarding response to immune checkpoint inhibitors. The presence of these alterations is associated with a younger age at diagnosis and shorter overall survival. These findings suggest that patients with STK11 alterations might benefit from alternative therapeutic approaches or stratification strategies in clinical trials, potentially justifying phase II/III trials for targeted therapies. Clinical impact could be seen in the medium term (3-5 years) for patient stratification. BIOMOL: The primary discovery is the significant enrichment of STK11 alterations (mutations and focal deletions) in HPV-positive cervical adenocarcinomas. The study also highlighted complex structural rearrangements of chromosome 19p involving STK11, which were not detected by exome sequencing alone, emphasizing the importance of whole-genome analyses. Co-occurrence with YAP1 amplification and mutual exclusivity with PIK3CA mutations were observed. Technologies used include whole-exome sequencing (WES), structural variation analysis via SNP-array, and whole-genome sequencing (WGS), enabling deep molecular characterization. These discoveries pave the way for identifying new therapeutic targets and molecular diagnostic tests for patient stratification. BIOINFO: The study employed a robust bioinformatic approach by combining whole-exome sequencing data with SNP-array and whole-genome sequencing analyses to detect complex structural variations. Replication of findings across large public and private cohorts (TCGA, AACR Project GENIE, MSKCC, Caris) totaling over 4600 samples strengthens the validity and generalizability of the discoveries. The integration of these diverse data sources and genomic analysis types allowed overcoming the limitations of WES alone for detecting chromosomal rearrangements, thereby improving the molecular characterization of tumors.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology